237 related articles for article (PubMed ID: 32915203)
1. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis.
Haas MK; Aiona K; Erlandson KM; Belknap RW
Clin Infect Dis; 2021 Nov; 73(9):e3459-e3467. PubMed ID: 32915203
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.
Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM
Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
Doan TN; Fox GJ; Meehan MT; Scott N; Ragonnet R; Viney K; Trauer JM; McBryde ES
J Antimicrob Chemother; 2019 Jan; 74(1):218-227. PubMed ID: 30295760
[TBL] [Abstract][Full Text] [Related]
4. High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.
Sandul AL; Nwana N; Holcombe JM; Lobato MN; Marks S; Webb R; Wang SH; Stewart B; Griffin P; Hunt G; Shah N; Marco A; Patil N; Mukasa L; Moro RN; Jereb J; Mase S; Chorba T; Bamrah-Morris S; Ho CS
Clin Infect Dis; 2017 Oct; 65(7):1085-1093. PubMed ID: 28575208
[TBL] [Abstract][Full Text] [Related]
5. Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.
Borisov AS; Bamrah Morris S; Njie GJ; Winston CA; Burton D; Goldberg S; Yelk Woodruff R; Allen L; LoBue P; Vernon A
MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(25):723-726. PubMed ID: 29953429
[TBL] [Abstract][Full Text] [Related]
6. Completion Rate and Safety of Tuberculosis Infection Treatment With Shorter Regimens.
Cruz AT; Starke JR
Pediatrics; 2018 Feb; 141(2):. PubMed ID: 29363561
[TBL] [Abstract][Full Text] [Related]
7. Improved treatment completion with shorter treatment regimens for latent tuberculous infection.
Macaraig MM; Jalees M; Lam C; Burzynski J
Int J Tuberc Lung Dis; 2018 Nov; 22(11):1344-1349. PubMed ID: 30355415
[TBL] [Abstract][Full Text] [Related]
8. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan.
Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM
Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940
[TBL] [Abstract][Full Text] [Related]
9. Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifapentine.
McClintock AH; Eastment M; McKinney CM; Pitney CL; Narita M; Park DR; Dhanireddy S; Molnar A
BMC Infect Dis; 2017 Feb; 17(1):146. PubMed ID: 28196479
[TBL] [Abstract][Full Text] [Related]
10. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
Surey J; Stagg HR; Yates TA; Lipman M; White PJ; Charlett A; Muñoz L; Gosce L; Rangaka MX; Francis M; Hack V; Kunst H; Abubakar I
BMC Infect Dis; 2021 Jan; 21(1):90. PubMed ID: 33478428
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
Ferguson O; Jo Y; Pennington J; Johnson K; Chaisson RE; Churchyard G; Dowdy D
J Int AIDS Soc; 2020 Oct; 23(10):e25623. PubMed ID: 33073520
[TBL] [Abstract][Full Text] [Related]
12. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study.
Lam CK; McGinnis Pilote K; Haque A; Burzynski J; Chuck C; Macaraig M
J Med Internet Res; 2018 Nov; 20(11):e287. PubMed ID: 30459146
[TBL] [Abstract][Full Text] [Related]
13. Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates.
Knoll BM; Nog R; Wu Y; Dhand A
Infection; 2017 Jun; 45(3):335-339. PubMed ID: 28276008
[TBL] [Abstract][Full Text] [Related]
14. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Semitala FC; Kadota JL; Musinguzi A; Nabunje J; Welishe F; Nakitende A; Akello L; Bishop O; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PPJ; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
PLoS Med; 2021 Dec; 18(12):e1003875. PubMed ID: 34914696
[TBL] [Abstract][Full Text] [Related]
15. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.
Winters N; Belknap R; Benedetti A; Borisov A; Campbell JR; Chaisson RE; Chan PC; Martinson N; Nahid P; Scott NA; Sizemore E; Sterling TR; Villarino ME; Wang JY; Menzies D
Lancet Respir Med; 2023 Sep; 11(9):782-790. PubMed ID: 36966788
[TBL] [Abstract][Full Text] [Related]
16. Treatment for Tuberculosis Infection With 3 Months of Isoniazid and Rifapentine in New York City Health Department Clinics.
Stennis NL; Burzynski JN; Herbert C; Nilsen D; Macaraig M
Clin Infect Dis; 2016 Jan; 62(1):53-59. PubMed ID: 26338781
[TBL] [Abstract][Full Text] [Related]
17. Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: A multicentre randomised controlled trial in Taiwan.
Sun HY; Huang YW; Huang WC; Chang LY; Chan PC; Chuang YC; Ruan SY; Wang JY; Wang JT
Tuberculosis (Edinb); 2018 Jul; 111():121-126. PubMed ID: 30029896
[TBL] [Abstract][Full Text] [Related]
18. Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada.
Moro RN; Borisov AS; Saukkonen J; Khan A; Sterling TR; Villarino ME; Scott NA; Shang N; Kerrigan A; Goldberg SV
Clin Infect Dis; 2016 Jun; 62(11):1390-1400. PubMed ID: 26951571
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
[TBL] [Abstract][Full Text] [Related]
20. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
Denholm JT; McBryde ES; Eisen D; Street A; Matchett E; Chen C; Shultz TR; Biggs B; Leder K
Intern Med J; 2017 Dec; 47(12):1433-1436. PubMed ID: 29224209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
